D33.7
BillableBenign neoplasm of other specified parts of central nervous system
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is D33.7 an HCC code?
Yes. D33.7 maps to Melanoma and Other Skin Cancers under the CMS-HCC V28 risk adjustment model (and Breast, Prostate, and Other Cancers and Tumors under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for D33.7
For D33.7 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed D33.7 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
D33.7 is the ICD-10-CM diagnosis code for benign neoplasm of other specified parts of central nervous system. A non-cancerous tumor of the central nervous system in locations not covered by the other specific codes. D33.7 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering benign neoplasms, except benign neuroendocrine tumors (d10-d36).
Under the CMS-HCC V28 risk adjustment model, D33.7 maps to Melanoma and Other Skin Cancers (HCC 23) with a community, non-dual, aged base RAF weight of 0.251. Under the older CMS-HCC V24 model, D33.7 maps to Breast, Prostate, and Other Cancers and Tumors (HCC 12) with a community, non-dual, aged base RAF weight of 0.150. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
This code is for other specified CNS sites; document the exact anatomical location in the medical record. Because D33.7 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for D33.7 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •This code is for other specified CNS sites; document the exact anatomical location in the medical record
- •Review documentation carefully to ensure a more specific code is not available before using this code
Clinical Significance
Benign neoplasm of other specified parts of the central nervous system captures benign tumors at CNS locations not covered by more specific codes, such as the cauda equina, filum terminale, or other atypical CNS sites. These are uncommon locations that may harbor ependymomas, schwannomas, or lipomas. Clinical significance depends heavily on the specific location and relationship to neural structures.
Documentation Requirements
- ✓Documentation must specify the CNS location and confirm benign histology through pathology or characteristic imaging features.
- ✓The exact anatomical site should be clearly recorded to justify use of this 'other specified' code rather than a more common category.
- ✓Include tumor dimensions, symptoms, and management plan.